Skip to search formSkip to main contentSkip to account menu

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).
View on PubMed (opens in a new tab)

Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1

A GA2LEN task force report concluded that chronic spontaneous urticaria is a “hidden epidemic” that needs to be addressed to address the unmet clinical needs of patients.
View on Wiley (opens in a new tab)

A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis.

This classification aid serves as a basic introduction into the field ofhair follicle morphogenesis, aims at standardizing the presentation of related hair research data, and should become a useful tool when screening new mouse mutants for discrete abnormalities of hair follicles morphogenesis in a highly reproducible, easily applicable, and quantifiable manner.
View on PubMed (opens in a new tab)

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

View on PubMed (opens in a new tab)

Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression

It is reported here that mouse or human mast cells can produce and secrete VPF/VEGF, and a new mechanism by whichmast cells can contribute to enhanced vascular permeability and/or angiogenesis, in both allergic diseases and other settings.
View PDF (opens in a new tab)

Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.

View on PubMed (opens in a new tab)

WAO Guideline for the Management of Hereditary Angioedema

A group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus meets criteria as a guideline.
View on Springer (opens in a new tab)

Schnitzler's syndrome: diagnosis, treatment, and follow‐up

First‐line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra and follow‐up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.
View on Wiley (opens in a new tab)

Pharmacology of Antihistamines

All H1-antihistamines have anti-inflammatory effects but it requires regular daily dosing rather than dosing 'on-demand' for this effect to be clinically demonstrable.
View on Springer (opens in a new tab)

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European…

View on PubMed (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)